Biotech | January 05, 2022
Biogen exercises option with Ionis for spinal muscular atrophy
Biogen paid Ionis a US $ 60 million one-time upfront payment
Biogen paid Ionis a US $ 60 million one-time upfront payment
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
It is a novel oral NLRP3 inflammasome inhibitor
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
EaseVRx employs the principles of cognitive behavioural therapy and other behavioural therapy techniques for the reduction of pain and pain interference
It provides an option to automatically perform nodule detection immediately after chest X-ray imaging
The youngest child in India to survive ECMO after undergoing bone marrow transplant for a rare disease
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.
Subscribe To Our Newsletter & Stay Updated
